Oral CGRP Shows Promising Results
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- About Migraine. Migraine Research Foundation. https://migraineresearchfoundation.org/about-migraine/migraine-facts/ 2019. Accessed August 30, 2019.
- Robbins L. A New Frontier in Migraine Management: Inside CGRP Inhibitors & Migraine Prevention. Practical Pain Management. https://www.practicalpainmanagement.com/pain/headache/new-frontier-migraine-management-inside-cgrp-inhibitors-migraine-prevention Published June 12, 2019. Accessed August 30, 2019.
- Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. NEJM. 2019, 381: 142-149. Doi: 10.1056/NEJMoa1811090. Published July 11, 2019. Accessed August 30, 2019.
- Terry M. Biohaven’s Rimegepant for Migraines Heads to the FDA for Approval Following Succcessful Trial. Biospace. https://www.biospace.com/article/biohaven-s-migraine-drug-shows-superiority-for-freedom-from-pain-in-phase-iii/ Published July 11, 2019. Accessed August 30, 2019.